Difference between revisions of "Part:BBa K4165051"

(Dry-lab Characterization)
 
(12 intermediate revisions by 2 users not shown)
Line 6: Line 6:
  
 
===Usage and Biology===
 
===Usage and Biology===
Switch 31 is used to mediate the activity of HTRA1. It is composed of 3 parts connected by different linkers; an HtrA1 PDZ peptide, a clamp of two targeting peptides for tau or amyloid beta, and a catalytic domain inhibitor. Activating HTRA1 requires a conformational change in the linker, eliminating the attached inhibitor from the active site. The conformational rearrangement can be mediated through the binding of affinity clamp to tau or beta-amyloid. This binding will result in a tension that detaches the inhibitor from the active site.
+
Switch # is used to mediate the activity of HTRA1. It is composed of 3 parts connected by different linkers; an HtrA1 peptide binding PDZ, a clamp of two targeting peptides for tau or amyloid beta, and a catalytic domain inhibitor. Activating HTRA1 upon clamp binding to the target protein requires a conformational change in the linker, eliminating the attached inhibitor from the active site. The conformational rearrangement can be mediated through the binding of affinity clamp to tau or beta-amyloid. This binding will result in a tension that detaches the inhibitor from the active site.
 +
 
 +
The seed peptide is considered as an amyloid binding peptide and is proved experimentally to inhibit the aggregations of amyloid beta through cell viability assays with a survival rate values nearly 100%. The H1A peptide was validated to bind with the PDZ of HtrA1 experimentally. The last part, which is the inhibitor, which is mainly a serine protease inhibitor, and since our protease is a serine protease, so it will act and inhibit the Protein. The whole construction was similarly proved from literature .The process of assembly of the whole switch was done according to both CAPRI and NCBI protocols.
  
  
 
<!-- -->
 
<!-- -->
 +
 
===<span class='h3bb'>Sequence and Features</span>===
 
===<span class='h3bb'>Sequence and Features</span>===
 
<partinfo>BBa_K4165051 SequenceAndFeatures</partinfo>
 
<partinfo>BBa_K4165051 SequenceAndFeatures</partinfo>
  
 
===Dry-lab Characterization===
 
===Dry-lab Characterization===
 +
 
<html>
 
<html>
<p><img src="https://static.igem.wiki/teams/4165/wiki/registry/dry-lab-modelling-pipeline.png" style="margin-left:200px;" alt="" width="500" /></p>
+
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/switches/switch31/switch31.png" style="margin-left:200px;" alt="" width="500" /></p>
 
</html>
 
</html>
 +
                                Figure 1.: Top 3D Model of switch 31 displayed in Pymol
  
 +
This switch was modeled by (Alphafold - Rosettafold - tRrosetta) and the top model was obtained from tRrosseta. the pipline for generating this model will be discussed in the next section in details.
  
                    Figure 1. A figure which dsecribes our Dry-Lab Modelling Pipeline. By team CU_Egypt 2022.
+
<h1>Switch construction Pipeline</h1>
  
<p style=" font-weight: bold; font-size:14px;"> Modeling </p>
+
<html>
 
+
<img src="https://static.igem.wiki/teams/4165/wiki/registry/dry-lab-modelling-pipeline.png" style="margin-left:200px;" alt="" width="500" /> <br>
The switch was modeled by (Alphafold - Rosettafold - tRrosetta) and the top model was obtained from tRrosseta.
+
</html>
  
  
 
+
                  Figure 2. A figure which describes our Dry-Lab Modelling Pipeline. By team CU_Egypt 2022.
<h1>Switch construction Pipeline</h1>
+
<html>
 
+
 
<p style=" font-weight: bold; font-size:14px;"> 1) Modelling </p>
 
<p style=" font-weight: bold; font-size:14px;"> 1) Modelling </p>
<p> Since our parts do not have experimentally acquired structures, we have to model them. This approach is done using both denovo modelling (ab initio) and template-based modelling. For modelling small peptides of our system we used AppTest and Alphafold.</p>
+
<p> Since our Switch parts (HTRA1 binding peptide, TAU, and Beta-amyloid Binding peptide) do not have experimentally acquired structures, we modeled each one of them separately. This approach is done using both denovo modeling (ab initio) and template-based modeling. For modeling small peptides of our system, we used AppTest and Alphafold.</p>
 
<p style=" font-weight: bold; font-size:14px;"> 2) Structure Assessment </p>
 
<p style=" font-weight: bold; font-size:14px;"> 2) Structure Assessment </p>
<p>In order to assess the quality of our structures we used the Swiss-Model tool which gives an overall on quality of any 3D structure (For more information: (Link modelling page).</p>
+
<p>In order to assess the quality of generated structures, we used the Swiss-Model tool, which gives an overall quality of any 3D structure (For more information, please check our 
 +
<a href="https://2022.igem.wiki/cu-egypt/ProteinModelling.html">Modeling page</a>.</p>
 
<p style=" font-weight: bold; font-size:14px;"> 3) Quality Assessment </p>
 
<p style=" font-weight: bold; font-size:14px;"> 3) Quality Assessment </p>
<p>Using the code created by us (CU_Egypt 2022), we use the JSON files created from the structure assessment step in Swiss-Model to rank all the models For more information: (Link software page) under the name of Modric.</p>
+
<p>Using the code created by us (CU_Egypt 2022), we use the JSON files created from the structure assessment step in Swiss-Model to rank all the models out of score 6. For more information: <a href="https://2022.igem.wiki/cu-egypt/ProgrammingClub.html">Programming club page code under the name of Modric.</a>.</p>
  
 
<p style=" font-weight: bold; font-size:14px;">4) Filtering</p>
 
<p style=" font-weight: bold; font-size:14px;">4) Filtering</p>
<p>We take the top ranked models from the previous steps.</p>
+
<p>We take the top-ranked models from the previous steps that have either a score of 5 or 6 </p>
  
 
<p style=" font-weight: bold; font-size:14px;">5) Docking</p>
 
<p style=" font-weight: bold; font-size:14px;">5) Docking</p>
<p>The top models of inhibitor and HTRA Binding Peptide are docked with HtrA1 (BBa_K4165004).</p>
+
<p>The top models of inhibitor and HTRA Binding Peptide are docked with HtrA1, and the top models of the clamps are docked with the Target protein, that is, in our case is Beta-amyloid (BBa_K4165004).</p>
  
 
<p style=" font-weight: bold; font-size:14px;">6) Ranking</p>
 
<p style=" font-weight: bold; font-size:14px;">6) Ranking</p>
<p>The docking results are ranked according to their PRODIGY results. For more information: (Link Docking page).</p>
+
<p>The docking results are ranked according to the Delta free energy generated by PRODIGY. For more information please check our <a href="https://2022.igem.wiki/cu-egypt/Docking.html">Docking page</a>.</p>
  
 
<p style=" font-weight: bold; font-size:14px;">7) Top Models</p>
 
<p style=" font-weight: bold; font-size:14px;">7) Top Models</p>
<p>The results that came out from PRODIGY are ranked and top models are chosen to proceed with to the next step. For more information: (Link Docking page).</p>
+
<p>The results from PRODIGY are ranked, and the top three models are chosen after the models are visualized to ensure that the proteins interact at the right designated domain to proceed with the next step. For more information please check our <a href="https://2022.igem.wiki/cu-egypt/Docking.html">Docking page</a>.</p>
  
 
<p style=" font-weight: bold; font-size:14px;">8) Alignment</p>
 
<p style=" font-weight: bold; font-size:14px;">8) Alignment</p>
<p>Docked structures are aligned. This means that the HtrA1- binding peptide complex is aligned with the second complex which is the HtrA1-inhibitor complex to check whether they binded to the same site or not.</p>
+
<p>Docked structures are aligned. This means that the HtrA1- binding peptide complex is aligned with the second complex, the HtrA1-inhibitor complex, to check whether they bonded to the same site.</p>
<html>
+
 
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/switches/switch31/picture10.png" style="margin-left:300px;" alt="" width="300" /></p>
+
 
 +
<img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/switches/switch31/picture10.png" style="margin-left:300px;" alt="" width="300" /></p>
 
</html>
 
</html>
  
  
                    Figure 2. Aligned structures of HtrA1 binding peptide 1 docked to HtrA1 and inhibitor docked to HtrA1.  
+
          Figure 3. Aligned structures of HtrA1 binding peptide 1 docked to HtrA1 and inhibitor docked to HtrA1.  
 +
<html>
 +
 
 
<p style=" font-weight: bold; font-size:14px;">9) Linker length</p>
 
<p style=" font-weight: bold; font-size:14px;">9) Linker length</p>
<p>The linker lengths are acquired by seeing the distance between the inhibitor and the HtrA1 binding peptide which is between both C terminals, N terminals, C- and N- terminal, and N- and C-terminals.</p>
+
<p>The linker lengths are acquired by seeing the distance between the inhibitor and the HtrA1 binding peptide between both C terminals, N terminals, C- and N- terminal, and N- and N- and C-terminals the linker length is calculated to be between 12.8 and 24.7 angstroms.</p>
 +
 
  
 
<p style=" font-weight: bold; font-size:14px;">10) Assembly</p>
 
<p style=" font-weight: bold; font-size:14px;">10) Assembly</p>
<p>After settling on the linkers lengths, now we will proceed to the assembly step of the whole system which is done using TRrosetta, AlphaFold, RosettaFold, and Modeller.</p>
+
<p>After settling on the linkers' lengths, we will now proceed to the assembly step of the whole system, which is done using TRrosetta, AlphaFold, RosettaFold, and Modeller.</p>
<html>
+
 
<p>a<img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/switches/switch31/ninhiibitor31-clamp.png" style="margin-left:50px;" alt="" width="150" />b<img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/htra1-bp/h1b.jpg" style="margin-left:50px;" alt="" width="150" />c<img src="https://static.igem.wiki/teams/4165/wiki/q8iub5-trrosetta-model3.png" style="margin-left:50px;" alt="" width="150" /></p>
+
 
 +
<p>a<img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/switches/switch31/ninhiibitor31-clamp.png" style="margin-left:50px;" alt="" width="150"/> b<img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/htra1-bp/h1b.jpg" style="margin-left:50px;" alt="" width="150" />c<img src="https://static.igem.wiki/teams/4165/wiki/q8iub5-trrosetta-model3.png" style="margin-left:50px;" alt="" width="150" /></p>
 
</html>
 
</html>
  
    Figure 3. a) Seed_GGSGGGGG_seed clamp b) HTRA Binding Peptide 1 c)WAP-four disulfide core domain 13 serine protease inhibitor.
+
  Figure 4. a) Seed_GGSGGGGG_seed clamp b) HTRA Binding Peptide 1 c) WAP-four disulfide core domain 13 serine protease inhibitor.
 +
<html>
 
<p style=" font-weight: bold; font-size:14px;">11) Structure Assessment</p>
 
<p style=" font-weight: bold; font-size:14px;">11) Structure Assessment</p>
<p>In order to assess the quality of our structures we used the Swiss-Model tool which gives an overall on quality of any 3D structure (For more information: (Link modelling page).</p>
+
<p>In order to assess the quality of our structures, we used the Swiss-Model tool, which gives an overall quality of any 3D structure (For more information, please check our <a href="https://2022.igem.wiki/cu-egypt/ProteinModelling.html">Modeling page</a>.</p>
  
 
<p style=" font-weight: bold; font-size:14px;">12) Quality Assessment </p>
 
<p style=" font-weight: bold; font-size:14px;">12) Quality Assessment </p>
<p>Using the code created by us (CU_Egypt 2022), we use the JSON files created from the structure assessment step in Swiss-Model to rank all the models For more information: (Link software page) under the name of Modric.</p>
+
<p>Using the code created by us (CU_Egypt 2022), we use the JSON files created from the structure assessment step in Swiss-Model to rank all the models For more information, please proceed to our <a href="https://2022.igem.wiki/cu-egypt/ProgrammingClub.html">Programming club</a> under the name of Modric.</p>
  
 
<p style=" font-weight: bold; font-size:14px;">13) Ranking</p>
 
<p>Using the code created by us (CU_Egypt 2022), we use the JSON files created from the structure assessment step in Swiss-Model to rank all the models For more information: (Link software page) under the name of Abu Trika.</p>
 
 
<p style=" font-weight: bold; font-size:14px;">Table 1. quality assessment parameters of switch 31.</p>
 
<p style=" font-weight: bold; font-size:14px;">Table 1. quality assessment parameters of switch 31.</p>
<html>
 
<style>
 
table, th, td {
 
  border:1px solid black; margin-left:auto;margin-right:auto;
 
}
 
</style>
 
<body>
 
 
<table style="width:65%">
 
<table style="width:65%">
 
<table>
 
<table>
Line 104: Line 106:
 
   </tr>
 
   </tr>
 
</table>
 
</table>
</body>
+
 
</html>
+
 
 
<p style=" font-weight: bold; font-size:14px;">14) Alignment</p>
 
<p style=" font-weight: bold; font-size:14px;">14) Alignment</p>
<p>The docked structures are then aligned and compared to the basic parts which are docked with protein of interest (HtrA1). The structures with least RMSD are chosen.</p>
+
<p>The docked structures are then aligned and compared to the basic parts, which are docked with the protein of interest (HtrA1). The structures with the least RMSD are chosen following the recommended range provided by CAPRI protocol.</p>
<html>
+
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/switches/switch31/switch31.png" style="margin-left:300px;" alt="" width="250" /></p>
+
</html>
+
                                        Figure 3. Structure of top model of switch 31.
+
 
<p style=" font-weight: bold; font-size:14px;">Table 2. RMSD calculated from alignment of switch 31 and its basic parts.</p>
 
<p style=" font-weight: bold; font-size:14px;">Table 2. RMSD calculated from alignment of switch 31 and its basic parts.</p>
<html>
+
 
 
<style>
 
<style>
 
table, th, td {
 
table, th, td {
Line 130: Line 128:
 
     <td>1.367</td>
 
     <td>1.367</td>
 
     <td>1.674</td>
 
     <td>1.674</td>
     <td>4.466</td>
+
     <td>6.089</td>
 
   </tr>
 
   </tr>
 
</table>
 
</table>
 
</body>
 
</body>
 
</html>
 
</html>
 +
===Conclusion===
 +
The top model was HtrA1 switch 10 (BBa_K4165030) since it was the best switch fulfilling the criteria of structure assessment, docking, and RMSD.
 +
===References===
 +
1. Lu, J., Cao, Q., Wang, C., Zheng, J., Luo, F., Xie, J., ... & Li, D. (2019). Structure-based peptide inhibitor design of amyloid-β aggregation. Frontiers in molecular neuroscience, 12, 54.
 +
 +
2. Romero-Molina, S., Ruiz-Blanco, Y. B., Mieres-Perez, J., Harms, M., Münch, J., Ehrmann, M., & Sanchez-Garcia, E. (2022). PPI-Affinity: A Web Tool for the Prediction and Optimization of Protein–Peptide and Protein–Protein Binding Affinity. Journal of Proteome Research.
 +
 +
3. Stein, V., & Alexandrov, K. (2014). Protease-based synthetic sensing and signal amplification. Proceedings of the National Academy of Sciences, 111(45), 15934-15939

Latest revision as of 03:30, 14 October 2022


HtrA1 Switch 31

This composite part consists of T7 promoter (BBa_K3633015), lac operator (BBa_K4165062), pGS-21a RBS (BBa_K4165016), 6x His-tag (BBa_K4165020), H1A (BBa_K4165000), GS Linker (BBa_K4165066), seed peptide (BBa_K4165012), GS Linker (BBa_K4165019), seed peptide (BBa_K4165012), GS Linker (BBa_K4165066), WAP inhibitor (BBa_K4165008), and T7 terminator (BBa_K731721).

Usage and Biology

Switch # is used to mediate the activity of HTRA1. It is composed of 3 parts connected by different linkers; an HtrA1 peptide binding PDZ, a clamp of two targeting peptides for tau or amyloid beta, and a catalytic domain inhibitor. Activating HTRA1 upon clamp binding to the target protein requires a conformational change in the linker, eliminating the attached inhibitor from the active site. The conformational rearrangement can be mediated through the binding of affinity clamp to tau or beta-amyloid. This binding will result in a tension that detaches the inhibitor from the active site.

The seed peptide is considered as an amyloid binding peptide and is proved experimentally to inhibit the aggregations of amyloid beta through cell viability assays with a survival rate values nearly 100%. The H1A peptide was validated to bind with the PDZ of HtrA1 experimentally. The last part, which is the inhibitor, which is mainly a serine protease inhibitor, and since our protease is a serine protease, so it will act and inhibit the Protein. The whole construction was similarly proved from literature .The process of assembly of the whole switch was done according to both CAPRI and NCBI protocols.


Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    INCOMPATIBLE WITH RFC[12]
    Illegal NheI site found at 589
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal NgoMIV site found at 572
    Illegal AgeI site found at 308
  • 1000
    COMPATIBLE WITH RFC[1000]

Dry-lab Characterization

                               Figure 1.: Top 3D Model of switch 31 displayed in Pymol 

This switch was modeled by (Alphafold - Rosettafold - tRrosetta) and the top model was obtained from tRrosseta. the pipline for generating this model will be discussed in the next section in details.

Switch construction Pipeline



                 Figure 2. A figure which describes our Dry-Lab Modelling Pipeline. By team CU_Egypt 2022.

1) Modelling

Since our Switch parts (HTRA1 binding peptide, TAU, and Beta-amyloid Binding peptide) do not have experimentally acquired structures, we modeled each one of them separately. This approach is done using both denovo modeling (ab initio) and template-based modeling. For modeling small peptides of our system, we used AppTest and Alphafold.

2) Structure Assessment

In order to assess the quality of generated structures, we used the Swiss-Model tool, which gives an overall quality of any 3D structure (For more information, please check our Modeling page.

3) Quality Assessment

Using the code created by us (CU_Egypt 2022), we use the JSON files created from the structure assessment step in Swiss-Model to rank all the models out of score 6. For more information: Programming club page code under the name of Modric..

4) Filtering

We take the top-ranked models from the previous steps that have either a score of 5 or 6

5) Docking

The top models of inhibitor and HTRA Binding Peptide are docked with HtrA1, and the top models of the clamps are docked with the Target protein, that is, in our case is Beta-amyloid (BBa_K4165004).

6) Ranking

The docking results are ranked according to the Delta free energy generated by PRODIGY. For more information please check our Docking page.

7) Top Models

The results from PRODIGY are ranked, and the top three models are chosen after the models are visualized to ensure that the proteins interact at the right designated domain to proceed with the next step. For more information please check our Docking page.

8) Alignment

Docked structures are aligned. This means that the HtrA1- binding peptide complex is aligned with the second complex, the HtrA1-inhibitor complex, to check whether they bonded to the same site.


         Figure 3. Aligned structures of HtrA1 binding peptide 1 docked to HtrA1 and inhibitor docked to HtrA1. 

9) Linker length

The linker lengths are acquired by seeing the distance between the inhibitor and the HtrA1 binding peptide between both C terminals, N terminals, C- and N- terminal, and N- and N- and C-terminals the linker length is calculated to be between 12.8 and 24.7 angstroms.

10) Assembly

After settling on the linkers' lengths, we will now proceed to the assembly step of the whole system, which is done using TRrosetta, AlphaFold, RosettaFold, and Modeller.

a bc

  Figure 4. a) Seed_GGSGGGGG_seed clamp b) HTRA Binding Peptide 1 c) WAP-four disulfide core domain 13 serine protease inhibitor.

11) Structure Assessment

In order to assess the quality of our structures, we used the Swiss-Model tool, which gives an overall quality of any 3D structure (For more information, please check our Modeling page.

12) Quality Assessment

Using the code created by us (CU_Egypt 2022), we use the JSON files created from the structure assessment step in Swiss-Model to rank all the models For more information, please proceed to our Programming club under the name of Modric.

Table 1. quality assessment parameters of switch 31.

cbeta_deviations clashscore molprobity ramachandran_favored ramachandran_outliers Qmean_4 Qmean_6
2 2.18 1.55 89.84 1.56 0.195965 0.196775

14) Alignment

The docked structures are then aligned and compared to the basic parts, which are docked with the protein of interest (HtrA1). The structures with the least RMSD are chosen following the recommended range provided by CAPRI protocol.

Table 2. RMSD calculated from alignment of switch 31 and its basic parts.

average RMSD from free HtrA binding peptide1 average RMSD from docked HtrA binding peptide1 RMSD from free seed peptide
1.367 1.674 6.089

Conclusion

The top model was HtrA1 switch 10 (BBa_K4165030) since it was the best switch fulfilling the criteria of structure assessment, docking, and RMSD.

References

1. Lu, J., Cao, Q., Wang, C., Zheng, J., Luo, F., Xie, J., ... & Li, D. (2019). Structure-based peptide inhibitor design of amyloid-β aggregation. Frontiers in molecular neuroscience, 12, 54.

2. Romero-Molina, S., Ruiz-Blanco, Y. B., Mieres-Perez, J., Harms, M., Münch, J., Ehrmann, M., & Sanchez-Garcia, E. (2022). PPI-Affinity: A Web Tool for the Prediction and Optimization of Protein–Peptide and Protein–Protein Binding Affinity. Journal of Proteome Research.

3. Stein, V., & Alexandrov, K. (2014). Protease-based synthetic sensing and signal amplification. Proceedings of the National Academy of Sciences, 111(45), 15934-15939